Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 49

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 49
---
 product inventions along with patent rights
for internal research and development. Upon receipt of approval of an MMA in each territory, as defined (e.g., United States,
European Union, China, Japan), the Company will be obligated to pay an approval fee of $100,000 per
territory up to a maximum of $300,000 in
aggregate, which has not yet been received as of March 31, 2025. Pursuant to the terms of License Agreement II, upon
commercialization, Company will pay a royalty of 1.5%
of net sales, as defined, in each territory to MCRI until such time as any product related to License Agreement II is no longer sold
in the respective territory.

Note 8 – Segment Report

The Company’s Chief Executive Officer serves
as the CODM and evaluates the financial performance of the business and makes resource allocation decisions on a consolidated basis.

The Company operates in one reportable segment,
related to pharmaceutical development, which includes all activities related to product candidate development. The determination of a
single reportable segment is consistent with the financial information regularly provided to the CODM, who reviews and evaluates net
loss for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future
periods. The measure of segment assets is reported on the accompanying condensed consolidated balance sheet as total assets.

23

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following
discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited
condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial
information and related notes included in our Annual Report on Form 10-K for fiscal 2024, which was filed with the Securities and Exchange
Commission, or the SEC, on March 28, 2025, or the Annual Report.

Special Note Regarding Forward-Looking Statements

All statements other than
statements of historical fact included in this Quarterly Report on Form 10-Q, including, without limitation, statements under “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business
strategy and the plans and objectives of management for future operations, are forward-looking statements. When used in this Quarterly
Report on Form 10-Q, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend